Interrogating differences in expression of targeted gene sets to predict breast cancer outcome

BackgroundGenomics provides opportunities to develop precise tests for diagnostics, therapy selection and monitoring. From analyses of our studies and those of published results, 32 candidate genes were identified, whose expression appears related to clinical outcome of breast cancer. Expression of these genes was validated by qPCR and correlated with clinical follow-up to identify a gene subset for development of a prognostic test.MethodsRNA was isolated from 225 frozen invasive ductal carcinomas,and qRT-PCR was performed. Univariate hazard ratios and 95% confidence intervals for breast cancer mortality and recurrence were calculated for each of the 32 candidate genes. A multivariable gene expression model for predicting each outcome was determined using the LASSO, with 1000 splits of the data into training and testing sets to determine predictive accuracy based on the C-index. Models with gene expression data were compared to models with standard clinical covariates and models with both gene expression and clinical covariates.ResultsUnivariate analyses revealed over-expression of RABEP1, PGR, NAT1, PTP4A2, SLC39A6, ESR1, EVL, TBC1D9, FUT8, and SCUBE2 were all associated with reduced time to disease-related mortality (HR between 0.8 and 0.91, adjusted p < 0.05), while RABEP1, PGR, SLC39A6, and FUT8 were also associated with reduced recurrence times. Multivariable analyses using the LASSO revealed PGR, ESR1, NAT1, GABRP, TBC1D9, SLC39A6, and LRBA to be the most important predictors for both disease mortality and recurrence. Median C-indexes on test data sets for the gene expression, clinical, and combined models were 0.65, 0.63, and 0.65 for disease mortality and 0.64, 0.63, and 0.66 for disease recurrence, respectively.ConclusionsMolecular signatures consisting of five genes (PGR, GABRP, TBC1D9, SLC39A6 and LRBA) for disease mortality and of six genes (PGR, ESR1, GABRP, TBC1D9, SLC39A6 and LRBA) for disease recurrence were identified. These signatures were as effective as standard clinical parameters in predicting recurrence/mortality, and when combined, offered some improvement relative to clinical information alone for disease recurrence (median difference in C-values of 0.03, 95% CI of -0.08 to 0.13). Collectively, results suggest that these genes form the basis for a clinical laboratory test to predict clinical outcome of breast cancer.

[1]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[2]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[3]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[4]  R. Minchin,et al.  Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. , 2010, Biochemical and biophysical research communications.

[5]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[6]  M. Cowles.  Modelling Survival Data in Medical Research (2nd ed.) (Book) , 2004 .

[7]  Hemant Ishwaran,et al.  Random Survival Forests , 2008, Wiley StatsRef: Statistics Reference Online.

[8]  Desombre Er.  Steroid receptors in breast cancer. , 1984, Monographs in pathology.

[9]  William D. Dupont,et al.  Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data , 2009 .

[10]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[11]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[12]  R. Nicholson,et al.  Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. , 2003, The Biochemical journal.

[13]  T. Yeatman,et al.  Deregulated expression of LRBA facilitates cancer cell growth , 2004, Oncogene.

[14]  S. Kim,et al.  Promoter hypomethylation of the N-acetyltransferase 1 gene in breast cancer. , 2008, Oncology reports.

[15]  R. Tibshirani.  The lasso method for variable selection in the Cox model. , 1997, Statistics in medicine.

[16]  D. Hein.  Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. , 2002, Mutation research.

[17]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[18]  M. Erlander,et al.  Laser capture microdissection and its applications in genomics and proteomics. , 2002, Methods in enzymology.

[19]  D.,et al.  Regression Models and Life-Tables , 2022 .

[20]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Crowe.  The Breast: Comprehensive Management of Benign and Malignant Diseases , 2004 .

[22]  C. Cordon-Cardo,et al.  A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.

[23]  Angeline S. Andrew,et al.  A novel survival multifactor dimensionality reduction method for detecting gene–gene interactions with application to bladder cancer prognosis , 2010, Human Genetics.

[24]  F. Motoi,et al.  LIV-1 enhances the aggressive phenotype through the induction of epithelial to mesenchymal transition in human pancreatic carcinoma cells. , 2009, International journal of oncology.

[25]  Glen Kristiansen,et al.  Systematic characterisation of GABRP expression in sporadic breast cancer and normal breast tissue , 2006, International journal of cancer.

[26]  Ian O Ellis,et al.  The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer , 2007, Molecular medicine.

[27]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  W. McGuire.  Estrogen receptors in human breast cancer. , 1973, The Journal of clinical investigation.

[29]  C. Wells,et al.  Predictive markers in breast cancer – the present , 2007, Histopathology.

[30]  R. Vessella,et al.  LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling , 2011, PloS one.

[31]  Robert F. Bonner,et al.  Laser Capture Microdissection: Molecular Analysis of Tissue , 1997, Science.

[32]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[34]  S. A. Andres,et al.  Molecular signatures of estrogen receptor-associated genes in breast cancer predict clinical outcome. , 2008, Advances in experimental medicine and biology.

[35]  S. A. Andres,et al.  Co-expression of genes with estrogen receptor-α and progesterone receptor in human breast carcinoma tissue , 2012, Hormone molecular biology and clinical investigation.

[36]  J. Stec,et al.  A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. , 2005, Endocrine-related cancer.

[37]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[38]  W. Hauck,et al.  Proportional hazards (Cox) regression , 1993, Journal of General Internal Medicine.

[39]  W. McGuire,et al.  Special report. Steriod receptors in breast cancer. , 1979, The New England journal of medicine.

[40]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[41]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[42]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Xiong Su,et al.  TBC1D3, a hominoid oncoprotein, is encoded by a cluster of paralogues located on chromosome 17q12. , 2006, Genomics.

[44]  B. Fisher,et al.  National Surgical Adjuvant Breast and Bowel Project , 2020, Definitions.

[45]  J. Goeman.  L1 Penalized Estimation in the Cox Proportional Hazards Model , 2009, Biometrical journal. Biometrische Zeitschrift.

[46]  E. Copeland,et al.  Book Review The Breast: Comprehensive management of benign and malignant diseases Second edition. Edited by Kirby I. Bland and Edward M. Copeland III. 1631 pp. in two volumes, illustrated. Philadelphia, W.B. Saunders, 1998. $225. 0-7216-6656-6 , 1999 .

[47]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[48]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[49]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[50]  G. Mills,et al.  Emerging role of RAB GTPases in cancer and human disease. , 2005, Cancer research.

[51]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[52]  Y. Benjamini,et al.  THE CONTROL OF THE FALSE DISCOVERY RATE IN MULTIPLE TESTING UNDER DEPENDENCY , 2001 .

[53]  Sandrine Dudoit,et al.  Resampling-Based Multiple Hypothesis Testing with Applications to Genomics: New Developments in the R/Bioconductor Package multtest , 2009 .

[54]  Armin A. Weiser,et al.  Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patients , 2005, International journal of cancer.

[55]  Fernando Rodrigues-Lima,et al.  Identification of the Xenobiotic-Metabolizing Enzyme Arylamine N-Acetyltransferase 1 as a New Target of Cisplatin in Breast Cancer Cells: Molecular and Cellular Mechanisms of Inhibition , 2008, Molecular Pharmacology.

[56]  Peter C Austin,et al.  Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortality. , 2004, Journal of clinical epidemiology.

[57]  J. Wittliff,et al.  A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen , 2011, Hormones & cancer.

[58]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[59]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .